CANCER TEST
CHOLANGIOCARCINOMA
BilliArray Basic & Broad
Information
Questions
Turn Around Time:
BiliArray Basic: 9 business days*
BiliArray Broad: 2 weeks*
* If the sample needs to be enriched to ensure successful results, we will contact you
I Choose to do
BiliArray Basic
With BiliArray Basic we focus on detecting the expression of 2 proteins and checking for the presence of mutations/rearrangements in 5 genes. We also check for microsatellite instability (MSI or MMR) .
Consult your Oncologist for the best choice and personalization for you. There is the possibility of further personalization of the tests.
In case your sample is not already at Microdiagnostics archive, please contact us immediately so that we can arrange for its safe and rapid transport to our laboratory. You will also need to quickly and easily complete the Consent Form.
The number and type of mutations examined is updated through a dynamic process in accordance with current scientific research. It should therefore be recognized that there is a possibility that the list of genes on the order form may have changed (genes added or removed) during the analysis of the sample in the laboratory.
BiliArray Broad
With BiliArray Broad, in addition to the aforementioned 5 genes, 2 proteins and screening for microsatellite instability (MSI or MMR) of Basic, screening for rearrangements in an additional 48 genes is added to the panel , providing an even more detailed and broad molecular profile of cholangiocarcinoma.
The BiliArray Broad test additionally determines the Tumor Mutation Burden (TMB) .
Consult your Oncologist for the best choice and personalization for you. There is the possibility of further personalization of the tests.
In case your sample is not already at Microdiagnostics archive, please contact us immediately so that we can arrange for its safe and rapid transport to our laboratory. You will also need to quickly and easily complete the Consent Form.
The number and type of mutations examined is updated through a dynamic process in accordance with current scientific research. It should therefore be recognized that there is a possibility that the list of genes on the order form may have changed (genes added or removed) during the analysis of the sample in the laboratory.
If you have been diagnosed with cholangiocarcinoma (diagnosis based on histological examination), it is recommended to determine the molecular profile of the cancer. This molecular test aims to detect whether the tumor exhibits microsatellite instability (MSI or MMR), protein expression disorders (PD-L1), or fusions/rearrangements and mutations in the genes IDH1,2, FGFR2, NTRK1,2,3, BRAF, KRAS, etc.
These mutations are closely correlated with the response of cholangiocarcinoma to the treatment that will be chosen.
Based on the determination of the molecular profile, the Oncologist is given the opportunity to choose the optimal chemotherapy regimen, immunotherapy, or targeted therapy.
Consult your Oncologist for the best option for you.
The tests are performed on the surgical specimen (paraffin cubes) or the biopsy material (paraffin cube) from which your histological examination was performed or on the aspiration material (FNAB, EBUS) from which your cytological examination was performed. In our fully integrated Laboratory, the pathologist selects the most appropriate & representative paraffin cube, ensuring that the most appropriate sample will be used for the tests. Qualitative and quantitative parameters are checked.
In case your sample is not already at Microdiagnostics archive, please contact us immediately so that we can arrange for its safe and rapid transport to our laboratory. You will also need to quickly and easily complete the Consent Form.
In our fully integrated Laboratory, we handle your sample in such a way as to minimize unnecessary waste and time:
- The paraffin cube is placed, if possible, once on the microtome for obtaining tissue sections, by experienced tissue technologists.
- Tissue sections are obtained sequentially in such a way as to ensure diagnosis and perform Immunohistochemistry if required.
- Ensuring preservation of tissue sections for further molecular testing.
- Pathologists perform microdissection to ensure the maximum amount of cancer cells possible, removing all other necrotic cells or normal tissue that could affect the validity of the results.
- The molecular biologist immediately processes the tissue in a fully controlled environment, using next-generation sequencing (NGS) or real-time polymerase chain reaction (Real-time PCR) to identify mutations in the genes of interest.
MSI is more common in colorectal cancer and endometrial cancer. MSI has also been observed in cervical cancer, stomach cancer, glioblastoma, melanoma, ovarian cancer, prostate cancer.
Frequently Asked Questions (FAQ)
If you have been diagnosed with cholangiocarcinoma (diagnosis based on histological examination), it is recommended to determine the molecular profile of the cancer. This molecular test aims to detect whether the tumor exhibits microsatellite instability (MSI or MMR), protein expression disorders (PD-L1), or fusions/rearrangements and mutations in the genes IDH1,2, FGFR2, NTRK1,2,3, BRAF, KRAS, etc.
These mutations are closely correlated with the response of cholangiocarcinoma to the treatment that will be chosen.
Based on the determination of the molecular profile, the Oncologist is given the opportunity to choose the optimal chemotherapy regimen, immunotherapy, or targeted therapy.
Consult your Oncologist for the best option for you.
The tests are performed on the surgical specimen (paraffin cubes) or the biopsy material (paraffin cube) from which your histological examination was performed or on the aspiration material (FNAB, EBUS) from which your cytological examination was performed. In our fully integrated Laboratory, the pathologist selects the most appropriate & representative paraffin cube, ensuring that the most appropriate sample will be used for the tests. Qualitative and quantitative parameters are checked.
In case your sample is not already at Microdiagnostics archive, please contact us immediately so that we can arrange for its safe and rapid transport to our laboratory. You will also need to quickly and easily complete the Consent Form.
Most of the time, the sample material we are called upon to handle is small because it has resulted from a minimally invasive method (needle biopsy, fluid aspiration, paraffin block with minimal material).
In our laboratory, Pathologists check in a timely manner whether the material to be examined is sufficient. If so, then a management algorithm is followed, with the aim of achieving the performance of multiple tests on the material (Immunohistochemistry, real-time PCR, NGS) in order to fully check the molecular profile of your tumor (proteins, genes, histological Grading).
In this case, and once sample enrichment manipulations have been exhausted, we contact your clinician to discuss alternative approaches in order to obtain the desired information to select the optimal treatment for you. Some examples:
- Performing an alternative test (e.g. Immunohistochemistry instead of PCR, or choosing Next Generation Sequencing (NGS)
- Performing Immunohistochemistry instead of FISH (Fluorescent In Situ Hybridization) and tubulin
- Possible blood sampling instead of tissue testing (liquid biopsy)
- Possible option to take a new biopsy or puncture
Contact us at 2310 23 22 72 and we will immediately assist you in quickly transporting the sample to our laboratory.
By cash, bank card, bank deposit, or Online interbank deposit.
One of the primary concerns at Microdiagnostics is the protection of your personal data as well as the strict observance of the conditions for the protection of your genetic material and medical results.
In full compliance with the General Data Protection Regulation (GDPR), we ensure that any test conducted is done with your knowledge and consent and we do not communicate results over the phone.